SavedAdd your journal

Journals / Southern Clinics of Istanbul Eurasia / 2019 / Cilt: 30 - Sayı: 3

Causes of Elevated Levels of Serum CA 19.9 in Patients without Prior Diagnosis of Malignant Disease

Daha Önce Malignite Tanısı Konmamış Hastalarda Yüksek Serum CA 19.9 Düzeylerinin Nedenleri

Tarkan YETİŞYİĞİT
Savaş GÜZEL
Sonat Pınar KARA
Ahsen YILMAZ
Selcuk ŞEBER
Pages
198–203
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Statistical analysis of marker levelsin relation to diagnosis of patients was performed.Results: Overall, 226 patients with benign disorders and 59 patients with malignant diseasehad elevated CA 19-9 levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Serum CA 19.9 is commonly used as a tumor marker for diagnosis and followup of gastrointestinal malignancies.
📊
Key Findings & Data:However, elevated levels can be found in various clinicalconditions.Methods: A total of 285 patients whose serum CA 19.9 level was ordered from variousoutpatient clinics other than oncology in a tertiary hospital setting and who had elevated CA19.9 (>34 U/mL) levels were included in the study group.
💡
Conclusion & Impact:Statistical analysis of marker levelsin relation to diagnosis of patients was performed.Results: Overall, 226 patients with benign disorders and 59 patients with malignant diseasehad elevated CA 19-9 levels.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Serum CA 19.9 is commonly used as a tumor marker for diagnosis and followup of gastrointestinal malignancies. However, elevated levels can be found in various clinicalconditions.Methods: A total of 285 patients whose serum CA 19.9 level was ordered from variousoutpatient clinics other than oncology in a tertiary hospital setting and who had elevated CA19.9 (>34 U/mL) levels were included in the study group. Statistical analysis of marker levelsin relation to diagnosis of patients was performed.Results: Overall, 226 patients with benign disorders and 59 patients with malignant diseasehad elevated CA 19-9 levels. One hundred ten (39%) patients with increased CA 19-9 levelsdid not have any significant clinical condition associated with high CA 19-9 values. MedianCA 19-9 levels were significantly higher in patients with malignancies than in patients withbenign disorders (67.3 vs. 47.9; p

Özet

Amaç: Serum CA 19.9 değerleri gastrointestinal sistem kaynaklı malignitelerin tanısı ve takibinde sık kullanılan bir tümör belirtecidir ancak pek çok farklı klinik durumda serum CA 19.9 değerlerinden yükseklikler ortaya çıkabilir. Gereç ve Yöntem: Onkoloji kliniği haricindeki polikliniklerden serum CA 19.9 düzeyi incelenmiş ve üst referans limitin üzerinde CA 19.9 değeri saptanmış olan toplam 285 hasta çalışma grubuna dahil edildi. CA 19.9 düzeyleri ile hastaların tanıları arasındaki olası ilişkiler istatistiksel analiz yöntemleriyle geriye dönük olarak incelendi. Bulgular: Hastaların 226’sında benign hastalıklar artmış CA 19.9 düzeyleri ile ilişki bulunmuş iken 59 hastada malignite saptandı. Yüz on (%39) hastada ise artmış CA 19.9 değerleri herhangi bir klinik durum ile ilişkilendirilmedi. Medyan serum CA 19.9 değerleri malign hastalığı olanlarda, diğer bireylere göre anlamlı olarak yüksek saptandı (67.3 ve 47.9; p

🔖

Cite This Article

YETİŞYİĞİT, T., GÜZEL, S., KARA, S. P., YILMAZ, A., ŞEBER, S. (2022). Causes of Elevated Levels of Serum CA 19.9 in Patients without Prior Diagnosis of Malignant Disease. Southern Clinics of Istanbul Eurasia, Cilt: 30 - Sayı: 3, 198–203. https://ajindex.com/articles/592835

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 1983;29:549–52
  2. Tuccillo FM, de Laurentiis A, Palmieri C, Fiume G, Bonelli P, Borrelli A,et al. Aberrant glycosylation as biomarker for cancer: focus on CD43. Biomed Res Int 2014;2014:742831
  3. McLaughlin R, O’Hanlon D, Kerin M, Kenny P, Grimes H, Given HF. Are elevated levels of the tumour marker CA19-9 of any clinical significance?--an evaluation. Ir J Med Sci 1999;168:124–6
  4. Luo G, Liu C, Guo M, Cheng H, Lu Y, Jin K, et al.Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Ann Surg 2017;265:800–805
  5. Scarà S, Bottoni P, Scatena R. CA 19 9: Biochemical and Clinical Aspects. Adv Exp Med Biol 2015;867:247–60
  6. Barnett D, Liu Y, Partyka K, Huang Y, Tang H, Hostetter G, et al. The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells. Sci Rep 2017;7:4020
  7. Lin MS, Huang JX, Yu H. Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker. Int J Clin Exp Med 2014;7:744–50
  8. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19:182–6
  9. Pavai S, Yap SF. The clinical significance of elevated levels of serum CA 19-9. Med J Malaysia 2003;58:667–72
  10. Morris-Stiff G, Teli M, Jardine N, Puntis MC. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreat Dis Int 2009;8:620–6
  11. Chen F, Shen J, Wang J, Cai P, Huang Y. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag Res 2018;10:1313–1318
  12. Coskun A, Kiran G, Ozdemir O. CA 19-9 can be a useful tumor marker in ovarian dermoid cysts. Clin Exp Obstet Gynecol 2008;35:137–9
  13. Takeshima N, Shimizu Y, Umezawa S, Hirai Y, Chen JT, Fujimoto I, et al. Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma. Gynecol Oncol 1994;54:321–6
  14. Kyung MS, Choi JS, Hong SH, Kim HS. Elevated CA 19-9 levels in mature cystic teratoma of the ovary. Int J Biol Markers 2009;24:52–6
  15. Matalliotakis IM, Goumenou AG, Mulayim N, Karkavitsas N, Koumantakis EE. High concentrat